Literature DB >> 24582867

Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.

Chelsea Zhang1, Laura J Havrilesky2, Gloria Broadwater3, Nicola Di Santo1, Jessie A Ehrisman1, Paula S Lee4, Andrew Berchuck4, Angeles Alvarez Secord4, Sarah Bean5, Rex C Bentley5, Fidel A Valea4.   

Abstract

OBJECTIVE: The aim of this study is to determine whether a minimally invasive approach to hysterectomy is associated with an increased rate of lymph vascular space invasion (LVSI) and/or malignant pelvic peritoneal cytology in endometrial cancer.
METHODS: We performed a single institution analysis of 458 women with endometrial cancer who underwent either total abdominal hysterectomy (TAH) or minimally invasive hysterectomy (MIH) with use of a disposable uterine manipulator. All patients had endometrial cancer diagnosed by endometrial biopsy at a single academic institution between 2002 and 2012. Exclusion criteria were pre-operative D&C and/or hysteroscopy, uterine perforation or morcellation, and conversion to laparotomy. Multivariate logistic regression models to determine if type of hysterectomy predicts either LVSI or presence of abnormal cytology were controlled for grade, stage, depth of invasion, tumor size, cervical and adnexal involvement.
RESULTS: LVSI was identified in 39/214 (18%) MIH and 44/242 (18%) TAH (p=0.99). Pelvic washings were malignant in 14/203 (7%) MIH and 16/241 (7%) TAH (p=1.0). Washings were atypical or inconclusive in 16/203 (8%) MIH and 6/241 (2.5%) TAH (p=0.014). In multivariate analyses, type of hysterectomy was not a significant predictor of either LVSI (p=0.29) or presence of malignant washings (p=0.66), but was a predictor of atypical or inconclusive washings (p=0.03).
CONCLUSION: Minimally invasive hysterectomy with use of a uterine manipulator for endometrial cancer is not associated with LVSI or malignant cytology. Algorithms that better determine the etiology and implications of inconclusive or atypical pelvic cytology are needed to inform the possible additional risk associated with a minimally invasive approach to endometrial cancer.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Endometrial cancer; Lymph vascular space invasion; Minimally invasive hysterectomy; Peritoneal cytology; Uterine manipulator

Mesh:

Year:  2014        PMID: 24582867     DOI: 10.1016/j.ygyno.2014.02.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Intraperitoneal cytology after laparoscopic hysterectomy in patients with endometrial cancer: A retrospective observational study.

Authors:  Tomohito Tanaka; Yoshito Terai; Kazuya Maeda; Keisuke Ashihara; Yuhei Kogata; Hiroshi Maruoka; Shinichi Terada; Takashi Yamada; Masahide Ohmichi
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

2.  Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.

Authors:  Benjamin B Albright; Jonathan D Black; Rachel Passarelli; Stefan Gysler; Margaret Whicker; Gary Altwerger; Gulden Menderes; Natalia Buza; Pei Hui; Alessandro D Santin; Masoud Azodi; Dan-Arin Silasi; Elena S Ratner; Babak Litkouhi; Peter E Schwartz
Journal:  Gynecol Oncol Rep       Date:  2018-01-09

3.  MR-Based Radiomics Nomogram of Cervical Cancer in Prediction of the Lymph-Vascular Space Invasion preoperatively.

Authors:  Zhicong Li; Hailin Li; Shiyu Wang; Di Dong; Fangfang Yin; An Chen; Siwen Wang; Guangming Zhao; Mengjie Fang; Jie Tian; Sufang Wu; Han Wang
Journal:  J Magn Reson Imaging       Date:  2018-10-26       Impact factor: 4.813

Review 4.  Role of uterine manipulator during laparoscopic endometrial cancer treatment.

Authors:  Vito Andrea Capozzi; Andrea Rosati; Stefano Uccella; Gaetano Riemma; Mattia Tarascio; Marco Torella; Pasquale De Franciscis; Nicola Colacurci; Stefano Cianci
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.